What is the recommended management for ependymoma?

Management of Ependymoma

Gross total resection (GTR) is the cornerstone of ependymoma management across all locations and grades, followed by risk-stratified radiotherapy based on tumor grade, location, and extent of resection 1.

Initial Surgical Management

Maximal safe surgical resection should be pursued as the primary treatment, as extent of resection is the single most important prognostic factor for both overall survival and progression-free survival across all ependymoma subtypes 1.

Key Surgical Principles:

• Perform postoperative MRI within 2-3 weeks to assess extent of resection (not earlier to avoid confusing postoperative changes with residual tumor) 1
• Consider second-look surgery when initial resection is incomplete and GTR appears achievable 1
• For spinal cord ependymomas, en bloc resection is preferred over piecemeal subtotal resection when feasible 1

Disease Staging (All Patients):

Mandatory staging includes craniospinal MRI and CSF cytology 2-3 weeks post-surgery due to CSF dissemination risk in all ependymoma patients, regardless of grade 1.

Intracranial Ependymomas - Adults

WHO Grade III (Anaplastic):

• Postoperative conformal radiotherapy up to 60 Gy is recommended regardless of extent of resection 1

WHO Grade II:

• After GTR: Watch-and-wait strategy (observation with serial MRI) 1
• After incomplete resection: Postoperative radiotherapy 54-59.4 Gy 1

CSF/Spinal Dissemination:

• Craniospinal irradiation 36 Gy with boost to 45-54 Gy on focal lesions 1

Intracranial Ependymomas - Children

Radiotherapy Dosing by Age:

• Children >3 years: 59.4 Gy in 1.8 Gy fractions (standard dose based on St. Jude data showing improved outcomes without increased neurocognitive deficits) 1
• Children 18 months to 3 years: 54 Gy (or older children with poor neurological status) 1
• Children 12-18 months: Consider 54 Gy or chemotherapy alone 1
• Children <12 months: Chemotherapy alone recommended to defer radiotherapy 1

Important caveat: Proton therapy may reduce neurocognitive sequelae by sparing supratentorial brain structures, though brainstem toxicity risks require careful dose limitation 1. The benefit-risk profile needs confirmation in prospective trials.

Chemotherapy Role:

Chemotherapy has NOT proven beneficial as adjuvant therapy in children >12 months and should not delay radiotherapy 1. Radiotherapy deferral strategies using chemotherapy have been abandoned in most institutions for children >12 months due to inferior outcomes 1.

Spinal Cord Ependymomas

WHO Grade II:

• After GTR: Watch-and-wait strategy 1
• After subtotal resection: Postoperative radiotherapy 45-54 Gy (extends median PFS from 48 to 96 months) 1

WHO Grade III (Anaplastic):

• Postoperative radiotherapy 45-54 Gy regardless of extent of resection 1

Myxopapillary Ependymoma (WHO Grade I):

• GTR is recommended whenever feasible 1
• After incomplete resection: Radiotherapy ≥50 Gy (increases 10-year PFS from <40% to 70%) 1
• High-dose radiotherapy (≥50 Gy) significantly improves local control without substantial late toxicity 1

Recurrent Disease Management

Treatment Algorithm for Recurrence:

1. Re-operation is first-line when feasible (5-year EFS of 19% with GTR vs 8% without repeat surgery in children) 1
2. Re-irradiation using fractionated or hypofractionated stereotactic techniques can achieve durable responses 1
3. Chemotherapy only after local treatment options exhausted 1

Chemotherapy Options (Limited Evidence):

• Temozolomide: Modest activity in chemo-naïve patients (22% response rate, median PFS 9.69 months), but minimal benefit in heavily pretreated patients 1
• Temozolomide + Lapatinib: Median PFS 45 weeks for WHO grade II, 25.3 weeks for grade III (responses correlate with ErbB2 expression) 1
• Continuous oral etoposide: May be active for recurrent spinal ependymomas 1
• Bevacizumab: Can provide clinical benefit in select patients 1

Long-Term Surveillance

All patients require lifelong enhanced MRI surveillance due to risk of asymptomatic and late relapses (can occur years after initial treatment) 1.

For children receiving radiotherapy: Serial monitoring of cognitive and endocrine functions is mandatory 1.

Critical Pitfalls to Avoid

1. Do not perform staging MRI/CSF cytology immediately post-surgery - wait 2-3 weeks to avoid false positives from surgical changes 1
2. Do not use chemotherapy to defer radiotherapy in children >12 months - this strategy has been abandoned due to inferior outcomes 1
3. Do not violate tumor capsule during spinal surgery - strong correlation with recurrence 1
4. Do not assume GTR eliminates need for radiotherapy in grade III tumors - radiotherapy is indicated regardless of resection extent 1